Jay R. Luly - Dec 16, 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
President and CEO, Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Dec 16, 2022
Transactions value $
-$918,806
Form type
4
Date filed
12/16/2022, 08:44 PM
Previous filing
Dec 5, 2022
Next filing
Dec 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $229K +16.1K +2.09% $14.18 790K Dec 16, 2022 Direct
transaction ENTA Common Stock Options Exercise $194K +13.9K +1.75% $14.00 804K Dec 16, 2022 Direct
transaction ENTA Common Stock Sale -$340K -7.8K -0.97% $43.59 796K Dec 16, 2022 Direct F1, F2
transaction ENTA Common Stock Sale -$383K -8.6K -1.08% $44.54 787K Dec 16, 2022 Direct F1, F3
transaction ENTA Common Stock Sale -$619K -13.6K -1.73% $45.49 774K Dec 16, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -16.1K -100% $0.00* 0 Dec 16, 2022 Common Stock 16.1K $14.18 Direct F5
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -13.9K -33.17% $0.00 27.9K Dec 16, 2022 Common Stock 13.9K $14.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $43.99, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.93, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.85, inclusive.
F5 100% of the shares subject to the option are fully vested and exercisable.
F6 On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable. The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. As of the date of this filing, a total of 50% of the shares subject to the option have become exercisable.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4 above.